Opinion|Videos|December 2, 2024
Nonestrogen Treatments for Menopause
Panelists discuss alternative therapies for women who are not candidates for or choose not to use hormonal therapy, review nonhormonal treatment options recommended by the North American Menopause Society, and explore the growing importance of Level I evidence and consensus opinions in creating a more holistic view of available therapies, both hormonal and nonhormonal.
Advertisement
Episodes in this series
Individualized therapy with shared decision-making is essential when evaluating the risk-benefit profile of hormonal therapy. What are some key considerations for a woman taking hormonal therapy?
- If a woman is not a candidate for hormonal therapy, or elects not to use it, what are some of the therapies/options available to her?
- What nonhormonal therapies are recommended by the North American Menopause Society?
- What is the importance of Level I evidence and consensus opinions?
- Are we moving toward a more holistic view of the evidence for all available therapies (both hormonal and nonhormonal)?
- Which of these are FDA approved?
Advertisement
Related to this article
Maternal RSV immunization creates an important opportunity for obstetric and pediatric clinicians to coordinate newborn prevention strategies, according to Kevin Ault, MD.
A new Gallup survey found 51% of women in the United States reported negative healthcare experiences.
Hugh Taylor, MD, explains that imaging in endometriosis is best for ruling out other causes of pelvic pain and cannot exclude the diagnosis.
A new study links earlier menopause age to faster cognitive decline and earlier Alzheimer diagnosis.
The FDA office of Women's Health and Center for Drug Evaluation and Research and hosting a public workshop with a focus on testosterone use in menopausal women.
Bruce Dorr, MD, FACOG, URPS, FMCP-M, weighs his own experience with pellet therapy against guideline evidence, then he and Maria Uloko, MD, close with candid advice for clinicians too afraid of hormones to start prescribing.
Bruce Dorr, MD, FACOG, URPS, FMCP-M, and Maria Uloko, MD, walk through real-world dosing, cost workarounds, and the labs that actually matter for safety and efficacy.
Bruce Dorr, MD, FACOG, URPS, FMCP-M, and Maria Uloko, MD, reframe testosterone candidacy around clinical presentation and hormone state, not age cutoffs or a single number on a chart.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Off-label testosterone dosing, access, and lab monitoring in the US
2
FDA holding public meeting on testosterone use in menopausal women
3
Kevin Ault, MD, on coordinating RSV prevention across maternal and pediatric care
4
Survey: 51% of US-women report negative healthcare experiences
5